InsiderTrades.com logo
Benjamin L. Palleiko net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Benjamin Palleiko Biography and Net Worth

Chief Executive Officer and Director of KalVista Pharmaceuticals

Ben is the Chief Executive Officer and a Director of KalVista. He joined the Company as Chief Financial Officer in August 2016 and was promoted to the additional role of Chief Business Officer in 2019, followed by President in 2023 and CEO in March 2024. His prior roles include SVP & CFO of Ore Pharmaceutical Holdings (Nasdaq: ORXE) and Penwest Pharmaceuticals Co. (Nasdaq: PPCO), and a decade as an investment banker at firms including Robertson Stephens. Before his business career, Ben served as a Naval Aviator in the U.S. Navy.

Ben holds a BA in Quantitative Economics from Tufts University as well as an MBA in Finance and an MA in International Relations from the University of Chicago.

What is Benjamin L. Palleiko's net worth?

The estimated net worth of Benjamin L. Palleiko is at least $8.57 million as of March 9th, 2026. Mr. Palleiko owns 451,815 shares of KalVista Pharmaceuticals stock worth more than $8,573,190 as of March 27th. This net worth approximation does not reflect any other investments that Mr. Palleiko may own. Learn More about Benjamin L. Palleiko's net worth.

How do I contact Benjamin L. Palleiko?

The corporate mailing address for Mr. Palleiko and other KalVista Pharmaceuticals executives is 55 Cambridge Parkway Suite 901E, CAMBRIDGE MA, 02142. KalVista Pharmaceuticals can also be reached via phone at 857-999-0075 and via email at [email protected]. Learn More on Benjamin L. Palleiko's contact information.

Has Benjamin L. Palleiko been buying or selling shares of KalVista Pharmaceuticals?

In the last ninety days, Benjamin L. Palleiko has sold $332,080.62 in KalVista Pharmaceuticals stock. Most recently, Benjamin L. Palleiko sold 6,693 shares of the business's stock in a transaction on Monday, March 9th. The shares were sold at an average price of $16.08, for a transaction totalling $107,623.44. Following the completion of the sale, the chief executive officer now directly owns 451,815 shares of the company's stock, valued at $7,265,185.20. Learn More on Benjamin L. Palleiko's trading history.

Who are KalVista Pharmaceuticals' active insiders?

KalVista Pharmaceuticals' insider roster includes Paul Audhya (Insider), Thomas Crockett (CEO), Edward Feener (Insider), Andreas Maetzel (SVP), Benjamin Palleiko (Chief Executive Officer and Director), Brian Piekos (CFO), Michael Smith (VP), Nicole Sweeny (Insider), and Christopher Yea (Insider). Learn More on KalVista Pharmaceuticals' active insiders.

Are insiders buying or selling shares of KalVista Pharmaceuticals?

During the last year, KalVista Pharmaceuticals insiders bought shares 1 times. They purchased a total of 25,000 shares worth more than $235,500.00. During the last year, insiders at the specialty pharmaceutical company sold shares 24 times. They sold a total of 140,441 shares worth more than $2,058,188.46. The most recent insider tranaction occured on March, 9th when CEO Benjamin L Palleiko sold 6,693 shares worth more than $107,623.44. Insiders at KalVista Pharmaceuticals own 4.3% of the company. Learn More about insider trades at KalVista Pharmaceuticals.

Information on this page was last updated on 3/9/2026.

Benjamin L. Palleiko Insider Trading History at KalVista Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/9/2026Sell6,693$16.08$107,623.44451,815View SEC Filing Icon  
2/23/2026Sell10,034$15.57$156,229.38442,883View SEC Filing Icon  
2/18/2026Sell1,038$15.00$15,570.00429,667View SEC Filing Icon  
2/12/2026Sell3,354$15.70$52,657.80428,286View SEC Filing Icon  
12/8/2025Sell7,294$16.51$120,423.94424,520View SEC Filing Icon  
11/24/2025Sell10,940$13.45$147,143.00416,189View SEC Filing Icon  
11/12/2025Sell3,328$11.55$38,438.40398,981View SEC Filing Icon  
9/8/2025Sell7,294$15.84$115,536.96395,189View SEC Filing Icon  
8/22/2025Sell10,940$13.22$144,626.80386,858View SEC Filing Icon  
7/9/2025Sell32,979$15.69$517,440.51369,595View SEC Filing Icon  
6/9/2025Sell7,169$14.50$103,950.50315,074View SEC Filing Icon  
5/19/2025Sell3,808$11.84$45,086.72293,367View SEC Filing Icon  
3/7/2025Sell6,669$11.97$79,827.93287,811View SEC Filing Icon  
2/18/2025Sell5,104$9.82$50,121.28278,855View SEC Filing Icon  
12/9/2024Sell7,627$9.75$74,363.25274,596View SEC Filing Icon  
11/18/2024Sell14,400$9.26$133,344.00266,598View SEC Filing Icon  
9/9/2024Sell7,352$12.19$89,620.88250,800View SEC Filing Icon  
8/19/2024Sell14,215$12.01$170,722.15242,527View SEC Filing Icon  
6/7/2024Sell7,465$11.53$86,071.45224,547View SEC Filing Icon  
5/20/2024Sell21,959$11.76$258,237.84216,387View SEC Filing Icon  
2/20/2024Sell22,802$14.11$321,736.22187,315View SEC Filing Icon  
8/18/2023Sell13,067$10.73$140,208.9195,254View SEC Filing Icon  
5/18/2023Sell4,037$10.14$40,935.1878,126View SEC Filing Icon  
2/17/2023Sell4,954$7.66$37,947.6472,799View SEC Filing Icon  
11/18/2022Sell722$5.44$3,927.6868,390View SEC Filing Icon  
2/23/2021Sell29,642$33.59$995,674.7894,642View SEC Filing Icon  
4/22/2019Sell3,073$25.70$78,976.1033,573View SEC Filing Icon  
4/18/2019Sell1,073$25.51$27,372.2333,573View SEC Filing Icon  
See Full Table

Benjamin L. Palleiko Buying and Selling Activity at KalVista Pharmaceuticals

This chart shows Benjamin L Palleiko's buying and selling at KalVista Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

KalVista Pharmaceuticals Company Overview

KalVista Pharmaceuticals logo
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $18.98
Low: $18.91
High: $19.95

50 Day Range

MA: $15.95
Low: $14.40
High: $18.95

2 Week Range

Now: $18.98
Low: $9.23
High: $19.95

Volume

1,014,265 shs

Average Volume

1,028,742 shs

Market Capitalization

$959.19 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A